Toggle Main Menu Toggle Search

Open Access padlockePrints

Cholinesterase inhibitors in dementia with Lewy bodies - A comparative analysis

Lookup NU author(s): Dr Elise Rowan, Professor Ian McKeith


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Objective To compare efficacy of different cholinesterase inhibitors (ChEls) for treating patients with dementia with Lewy bodies (DLB). Design Retrospective comparison of three independent clinical studies of ChEI treatment using donepezil, galantamine or rivastigmine in patients with DLB. Method Data was obtained from open label trials of donepezil and galantamine and a placebo controlled randomized trial of rivastigmine in DLB. Changes in Mini Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI) and United Parkinson's Disease Rating Scale (UPDRS-III) scores were compared between the three treatments at 12 and 20 weeks. Results All ChEls significantly improved cognitive and neuropsychiatric measures. Reduction in the total NPI score appeared significantly greater after donepezil treatment. There was no significant increase in UPDRS-III scores. Conclusions It is unclear to what extent these findings reflect true differences between ChEls or are due to methodological artefacts of comparing different studies. There is so far no compelling evidence that any one ChEI is better than the other in treating DLB but head to head comparative studies of different ChEls are warranted to clarify this. Copyright (c) 2007 John Wiley & Sons, Ltd.

Publication metadata

Author(s): Bhasin M, Rowan E, Edwards K, McKeith I

Publication type: Article

Publication status: Published

Journal: International Journal of Geriatric Psychiatry

Year: 2007

Volume: 22

Issue: 9

Pages: 890-895

ISSN (print): 0885-6230

ISSN (electronic): 1099-1166

Publisher: John Wiley & Sons Ltd.


DOI: 10.1002/gps.1759


Altmetrics provided by Altmetric


Funder referenceFunder name
G0400074Medical Research Council
G0502157Medical Research Council